This is a preview of subscription content, log in via an institution to check access.
Notes
National Health Service
Reference
NICE Consortium. NICE Backs Crysvita(Rm) (Burosumab) for Rare Metabolic Bone Disorder, X-linked Hypophosphataemia (XLH). Internet Document : 5 Sep 2018. Available from: URL: http://www.nice.org.uk
Rights and permissions
About this article
Cite this article
NICE recommends burosumab for X-linked hypophosphataemia. PharmacoEcon Outcomes News 812, 38 (2018). https://doi.org/10.1007/s40274-018-5305-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5305-4